ARWR vs TGTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ARWR · Arrowhead Pharmaceuticals$58.16 ▲ 1.22%
TGTX · TG Therapeutics$59.83 ▲ 3.18%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ARWR +45.9%
- TGTX +97.4%
Head to head
| Metric | ARWR | TGTX |
|---|---|---|
| Price | $58.16 | $59.83 |
| Change today | ▲ 1.22% | ▲ 3.18% |
| Market cap | $8.22B | $9.16B |
| Return, 3 months | -34.2% | +21.7% |
| Return, year to date | -12.4% | +100.7% |
| Return, 1 year | +48.3% | +85.6% |
| P/E (TTM) | -25.5 | 21.8 |
| P/B | 17.6 | 15.2 |
| P/E percentile vs own 5y | 31st | 73rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +171.0% | +70.3% |
| Net profit growth (YoY) | -0.1% | -72.4% |
| Gross margin | – | 82.4% |
| Operating margin | -33.8% | 17.1% |
| Net margin | -47.8% | 55.2% |
| Return on equity | -64.8% | 100.3% |
| Analyst target vs. price | +87.4% | +8.7% |
| Analyst buy share | 92% | 80% |
| RSI (14) | 40 | 59 |
| 30-day volatility | 37.2% | 40.4% |
| Max drawdown, 1 year | -37.6% | -22.5% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TGTX is the largest of the group by market value.
- TGTX has returned the most over the past year.
- ARWR carries the lowest trailing P/E.
- ARWR is growing revenue fastest.
- TGTX keeps the most profit per dollar of sales.
- ARWR has been the calmest stock over the last 30 days.